Celcuity Inc
XNAS:CELC 4:00:00 PM EDT
| Market Cap (Intraday) | 3.90B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $81.98 |
| 50-Day MA | $88.34 |
| 200-Day MA | $104.96 |
Celcuity Inc Stock, XNAS:CELC
16305 36th Avenue North, Suite 100, Minneapolis, Minnesota 55446
United States of America
Phone: +1.763.392.0767
Number of Employees: 55
Description
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.